CTIS2023-505477-33-00招募中1 期
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(ies) (KEEPsAKE 2) - M15-998
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 333
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) at Screening Visit., Subject has active disease at Baseline, Diagnosis of active plaque psoriasis with at least one psoriatic plaque of = 2 centimeter (cm) diameter or nail changes consistent with psoriasis at Screening Visit., Subject has demonstrated an inadequate response or intolerance to biologic therapy(ies) or csDMARD therapy(ies).
排除标准
- •Subject is considered by investigator, for any reason, to be an unsuitable candidate for the study., Subject has a known hypersensitivity to risankizumab.
研究者
相似试验
进行中（未招募）
1 期
A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)Moderately to Severely Active Rheumatoid Arthritis (RA)MedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-003332-13-SKAbbVie Deutschland GmbH & Co. KG600
进行中（未招募）
1 期
A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)Moderately to Severely Active Rheumatoid Arthritis (RA)MedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-003333-95-FIAbbVie Deutschland GmbH & Co. KG1,500
进行中（未招募）
1 期
A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who have not Previously taken Methotrexate (SELECT-EARLY)Moderately to Severely Active Rheumatoid Arthritis (RA)MedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-003334-27-ESAbbVie Deutschland GmbH & Co. KG800
进行中（未招募）
1 期
A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)EUCTR2015-003376-75-ESAbbVie Deutschland GmbH & Co. KG600
进行中（未招募）
1 期
A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)Moderately to Severely Active Rheumatoid Arthritis (RA)MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-003332-13-FIAbbVie Deutschland GmbH & Co. KG600